Home Business U.S. FDA approves Bluebird bio’s gene therapy for a rare neurological disorder
Business

U.S. FDA approves Bluebird bio’s gene therapy for a rare neurological disorder

By
Posted on September 17, 2022
1 min read
Comments Off on U.S. FDA approves Bluebird bio’s gene therapy for a rare neurological disorder
0
68

[ad_1]

Sept 16 – The U.S. Food and Drug Administration has approved bluebird bio’s gene therapy for the treatment of a rare neurological disorder, the company said late on Friday.

“SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys” with early, active Cerebral Adrenoleukodystrophy (CALD), the company said in a statement, saying CALD is a “devastating and fatal neurodegenerative disease.”

(Reporting by Mrinalika Roy and Jaiveer Shekhawatin in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and William Mallard)

[ad_2]

Source link

Load More Related Articles
Load More By 
Load More In Business
Comments are closed.

Check Also

When is the Right Time of Year to Transport Your Vehicle?

Transporting a vehicle can be a stressful experience, especially if you are unsure about t…